Opinion: Pfizer's Dividend Riskier Than It Looks, Even with a 7% Yield
Pfizer’s high dividend yield is eye-catching, but a big payout can hide hidden risks. This article explains the warni...
These tips reinforce discipline, such as setting clear categories, automating transfers, and reviewing results monthly.
17,300 articlesPfizer’s high dividend yield is eye-catching, but a big payout can hide hidden risks. This article explains the warni...
In 2026, two very different healthcare players—Abbott Laboratories and Glaukos—offer contrasting paths to potential g...
Earnings beats aren’t enough to steady markets as stocks see bigger, more persistent swings. The article explains wha...
A little known tax rule lets certain RV loans qualify for the mortgage interest deduction. As rates move with the eco...
From a tiny boat-insurer niche to a public company, Hagerty’s story is a case study in branding, community, and strat...
A quiet pivot from consumer devices to AI infrastructure has propelled this former smartphone maker into the spotligh...
Bank of America named two new leaders to oversee digital assets and AI transformation, signaling a strategic push to ...
Want anchors in a stormy market? Meet three dividend stocks never sell. These blue-chip picks blend reliable cash flo...
XOVR, the $1.5 billion ETF that blends pre-IPO SpaceX exposure with public-growth stocks, is drawing renewed scrutiny...
AppLovin reported its best quarter in history, with record revenue and an 84% EBITDA margin, but the stock declined s...
VOOG surged in a blistering rally before facing headwinds as rates climbed and big tech leadership shifted. Here's wh...
In this in-depth millionaire interview, we chat with a seasoned investor who turned savvy saving into a durable fortu...